Selective LMP7 Inhibitor Solid Forms for Proteasome Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors, such as bortezomib, lack selectivity for the immunoproteasome, leading to broad inhibition of both constitutive and immunoproteasomes, resulting in significant side effects like thrombocytopenia, neutropenia, and peripheral neuropathy, and do not distinguish between the two forms effectively.
Innovation Solution
Development of solid forms of [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, specifically in trimeric adduct, hydrate, anhydrous, and boronic acid ester forms, which act as selective inhibitors of the LMP7 subunit of the immunoproteasome, minimizing side effects by targeting the immunoproteasome specifically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum proteasome inhibitors like bortezomib are used, then inhibition of proteasome activity is achieved, but selectivity between constitutive and immunoproteasome is lost, leading to significant side effects
Solution Approach 1:
The patent applies local quality by designing the boronic acid compound with specific structural features (substituted phenyl ring, specific stereochemistry at positions 1, 2, and 4) that create localized interaction characteristics. This enables the molecule to selectively bind to the LMP7 subunit of the immunoproteasome while avoiding constitutive proteasome, thus achieving local selectivity at the target binding site that eliminates harmful side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the boronic acid compound through various substitutions (R1-R6 groups) and stereochemical configurations. These structural parameter changes enable fine-tuning of the compound's affinity and selectivity for the immunoproteasome LMP7 subunit, allowing differentiation from constitutive proteasome binding while maintaining effective inhibition.
2Reliability
If current proteasome inhibitors are used, then proteasome activity is inhibited, but discrimination between the two proteasome forms is not achieved
Solution Approach 1:
The compound design incorporates specific local structural features including the substituted phenyl ring system and chiral centers that create a unique binding geometry. This local quality enables precise recognition of the LMP7 subunit's active site architecture, achieving high selectivity for the immunoproteasome form while excluding constitutive proteasome binding, thus resolving the discrimination problem.
Solution Approach 2:
The patent utilizes asymmetry through the chiral centers at positions 1, 2, and 4 of the boronic acid compound. This asymmetric structure creates a non-superimposable binding configuration that specifically fits the LMP7 subunit's asymmetric active site, enabling stereoselective inhibition of the immunoproteasome while avoiding constitutive proteasome, thereby achieving precise form discrimination.
Data Source
AI summary
A solid form of [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, hydrates, solvates, and/or adducts thereof can be used as LMP7 inhibitors. The solid form can be a trimeric crystalline anhydrous form characterized by two or more 2θ XRPD peaks at 6.5±0.2°, 11.2±0.2°, 17.1±0.2°, 19.6±0.2°, and 21.9±0.2° degrees.